The heart of our approach is using collaboration to assemble a powerful structure-based drug discovery engine. Our ‘special sauce’ is applying that engine and our unique collective expertise to drive target selection and the design of novel molecules that become breakthrough medicines.
We identify targets known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. Our targets play causal roles in diseases of immunology, oncology and metabolism; drugging them with efficacious small molecules has the potential to transform patients’ lives.
STRUCTURE-BASED DRUG DISCOVERY ENGINE
We apply leading-edge computational chemistry, in concert with other technologies, to more effectively use protein structure to drug targets and modulate their functional activity.
We deploy a range of technologies, including X-ray crystallography and cryo-electron microscopy (cryo-EM) to generate atomic-resolution structural data on our targets — in some cases, for proteins that have never before been successfully mapped.
We leverage the technology of our founding partner Schrödinger to perform physics-based analyses of our targets’ active and allosteric sites and to design small molecule modulators with the desired binding mode, functional activity and selectivity.
Our comprehensive expertise spans protein science, biophysics, enzymology and screening. This assures the optimization of our therapeutic candidates across a stringent set of drug-like properties.
Breakthroughs by design
Our resulting potent and selective small molecule compounds provide the means for us to gain a deeper understanding of biology and develop new therapies for clinical evaluation in patients.